Urological Oncology

Are Hypoechoic Lesions on Transrectal Ultrasonography a Marker for Clinically Significant Prostate Cancer?

Tae Il Noh1, Yoon Sun Shin2, Ji Sung Shim1,3, Jong Hyun Yoon4, Jae Heon Kim5, Jae Hyun Bae1,3, Du Geon Moon3, Jae Young Park1,3

1Department of Urology, Korea University Ansan Hospital, Ansan, 2Korea University School of Medicine, Seoul, 3Department of Urology, Korea University College of Medicine, Seoul, 4Department of Urology, National Medical Center, Seoul, 5Department of Urology, Soonchunhyang University Seoul Hospital, Seoul, Korea

Purpose: To investigate the relationship of transrectal ultrasound (TRUS) findings with the pathological characteristics of prostate cancer (PCa).

Materials and Methods: The study was conducted retrospectively by analyzing the data for 970 patients who underwent prostate biopsies. Gleason scores and other clinical variables were compared between PCa patients with and without hypoechoic lesions on TRUS.

Results: Of the 970 patients, PCa was diagnosed in 291 (30%). Of these, high-grade PCa (Gleason score of 7 or more) was diagnosed in 190 (65%). The cancer detection rate was higher in patients with hypoechoic lesions (43.9%) than in those without hypoechoic lesions (21.4%, \(p < 0.001\)). High-grade PCa was detected more often in patients with hypoechoic lesions than in those without hypoechoic lesions (\(p < 0.001\)). Independent predictors for high-grade PCa by logistic regression analysis included hypoechoic lesions on TRUS and abnormal digital rectal examination findings.

Conclusions: Patients with PCa who had hypoechoic lesions on TRUS had more aggressive pathological disease than did those without lesions. Therefore, hypoechoic lesions on TRUS could be a marker for clinically significant PCa.

Keywords: Clinical marker; Prostate neoplasms; Ultrasonography

INTRODUCTION

Since Watanabe et al. [1] initially applied imaging methods in the prostate, the value of transrectal ultrasound (TRUS) for the detection and evaluation of prostate cancer (PCa) has been reported [2,3]. Although the efficacy of screening for PCa is under continuous debate [4,5], the advent of TRUS has improved visualization of prostate lesions. Hypoechoic lesions found during TRUS, as well as high levels of serum prostate-specific antigen (PSA) and abnormal digital rectal examination (DRE) findings, are the typical findings considered to be suspicious for PCa, and TRUS-guided prostate biopsy is generally recommended. There has been some controversy over TRUS owing to its low specificity and sensitivity; hence, new methods and imaging techniques are being intensely explored by investigators [6-9]. However, as previously reported in many studies, TRUS-guided biopsy is a widely practiced method for histological diagnosis in men with suspected PCa [10,11].

Although TRUS has significantly improved the diagnostic rate, the correlation between findings on TRUS and clinically significant PCa is incompletely understood. The aim of this study was to investigate the relationship of TRUS findings with the pathological characteristics of PCa.

MATERIALS AND METHODS

A total of 996 patients who had lesions suspected of being PCa (with a PSA level \(\geq 4.0\) ng/mL, a palpable nodule upon
DRE, or a hypoechoic lesion upon TRUS) underwent TRUS-guided prostate biopsy between January 2004 and December 2010. Men were excluded from the analysis if they had previously undergone prostate biopsy, had received a prior diagnosis of PCa, or had undergone prostate surgery or radiation treatment. A total of 970 men met the criteria and constituted the study cohort. According to the IRB approval (IRB No. GR10070-001), the clinical data were collected retrospectively. Informed consent was exempted by the board.

The methods of TRUS-guided biopsy were as follows. The rectum was cleaned with 10% povidone iodine and prophylactic antibiotics were administered before the TRUS-guided biopsy. All biopsies were performed with an automatic 18-gauge biopsy needle (Bard Urological Division, Covington, GA, USA) in conjunction with a Hawk 2102EXL medical ultrasound scanner (BK Medical A/S, Herlev, Denmark). TRUS was performed by using a 7.5-MHz biplane or multiplanar probe. Specimens of 10 cores were taken from the prostate of patients with suspected PCa. The biopsy specimens were examined for the presence of cancer and were categorized by Gleason score by a pathologist.

The positive predictive value of hypoechoic lesions on TRUS for PCa was calculated. The Gleason score was compared between PCa patients with or without hypoechoic lesions. The factors we evaluated for the risk of high-grade PCa included age, abnormal DRE result, PSA, prostate volume, transitional zone (TZ) volume, PSA density (PSAD), PSAD of the TZ (PSAD-TZ), and hypoechoic lesion on TRUS.

Continuous variables were expressed as either the mean±standard deviation or the median (interquartile range). Categorical variables were reported as the number of occurrences and frequency. Student t-test and the Pearson chi-square test were used for statistical comparisons of continuous and categorical variables, respectively. Simple and multiple logistic regressions with a backward variable selection procedure were performed to identify independent predictors of high-grade PCa. All statistical outcomes were presented as the odds ratio and the 95% confidence interval based on a two-sided test using SPSS 12.0 (SPSS Inc., Chicago, IL, USA). We regarded a p-value < 0.05 as statistically significant.

RESULTS

Among the 970 patients, PCa was diagnosed in 291 (30%). PCa was detected in 163 patients among 371 patients who had hypoechoic lesions on TRUS (positive predictive value, 43.9%), which was higher than the cancer detection rate in patients without hypoechoic lesions (21.4%, p < 0.001). Of the 163 patients with PCa who had hypoechoic lesions, 122 patients had a Gleason score of 7 or more. Of 128 patients with PCa who did not have hypoechoic lesions, 68 men had a Gleason score of 7 or more (p < 0.001). The detailed results of the patients’ characteristics and pathologic findings of PCa is described in Table 1.

A comparison was made among the 291 patients in whom PCa was diagnosed according to Gleason scores (Table 2). There were more patients with hypoechoic findings on TRUS among the patients with a Gleason score of 7 or more than among those with lower Gleason scores (p < 0.001). Patients with high-grade PCa also had higher ages, more abnormal DRE findings, and higher levels of PSA, PSAD, and PSAD-TZ (p < 0.05).

Logistic regression analysis was also performed among the 291 patients. In the simple logistic regression analysis, age, abnormal DRE findings, PSA, prostate volume, TZ volume, PSAD, PSAD-TZ, and hypoechoic lesions on TRUS were significant factors for high-grade PCa (Gleason score ≥7, Table 3). In the multiple logistic regression analysis, abnormal DRE findings and hypoechoic lesions on TRUS were identified as significant factors.

The numbers of biopsied men with a PSA level < 4 ng/mL, normal DRE findings, and a hypoechoic lesion on TRUS

---

Table 1: Clinical characteristics of the study cohort and differences between the groups by transrectal ultrasonographic findings

| Variable                  | All cases (n=970) | Normal TRUS (n=599) | Abnormal TRUS (n=371) | p-value |
|---------------------------|------------------|---------------------|-----------------------|---------|
| Age (y)                   | 65.9±8.95        | 64.7±9.22           | 67.8±8.15             | <0.001  |
| Nodule on DRE             | 215 (22.2)       | 68 (11.4)           | 147 (39.6)            | <0.001  |
| PSA (ng/mL)               | 6.66 (4.48-11.85)| 5.87 (4.19-9.14)    | 9.20 (5.24-26.44)     | 0.004   |
| Prostate volume (cm³)     | 39.0 (28.6-52.7) | 40.3 (29.0-54.7)    | 36.9 (28.0-50.0)      | 0.243   |
| Transitional zone volume  | 17.5 (10.9-27.6) | 18.2 (11.0-28.9)    | 16.9 (10.8-26.2)      | 0.030   |
| PSAD (ng/mL/cm³)          | 0.17 (0.10-0.32) | 0.14 (0.10-0.24)    | 0.25 (0.13-0.71)      | 0.002   |
| PSAD-TZ (ng/mL/cm³)       | 0.38 (0.21-0.84) | 0.32 (0.19-0.58)    | 0.57 (0.28-1.92)      | 0.003   |
| Patients with PCa         | 291 (30.0)       | 128 (21.4)          | 163 (43.9)            | <0.001  |
| Gleason score             |                  |                     |                       | <0.001  |
| ≤6                        | 101              | 60                  | 41                    |         |
| 7                         | 46               | 21                  | 25                    |         |
| ≥8                        | 144              | 47                  | 97                    |         |

Values are presented as mean±standard deviation, number (%) or median (interquartile range).
TRUS, transrectal ultrasound; DRE, digital rectal examination; PSA, prostate-specific antigen; PSAD, PSA density; PSAD-TZ, PSAD of transition zone volume; PCa, prostate cancer.
TABLE 2. Clinical characteristics of patients with prostate cancer according to Gleason score

| Variable                        | Gleason score ≤ 6 (n=101) | Gleason score ≥ 7 (n=190) | p-value |
|---------------------------------|---------------------------|---------------------------|---------|
| Age (y)                         | 66.5±7.61                 | 69.6±7.98                 | 0.001   |
| Nodule on DRE                   | 30 (29.7)                 | 102 (53.7)                | <0.001  |
| PSA (ng/mL)                     | 7.31 (5.31–14.3)          | 30.4 (11.1–99.4)          | 0.004   |
| Prostate volume (cm³)           | 31.2 (25.3–43.7)          | 34.7 (25.5–49.6)          | 0.317   |
| Transitional zone volume (cm³)  | 13.3 (9.17–20.9)          | 15.4 (9.70–22.8)          | 0.371   |
| PSAD (ng/mL/cm³)                | 0.24 (0.16–0.43)          | 0.93 (0.35–2.37)          | <0.001  |
| PSAD-TZ (ng/mL/cm³)             | 0.57 (0.35–1.17)          | 2.19 (0.82–5.20)          | <0.001  |
| Hypoechoic lesion on TRUS       | 41 (40.6)                 | 122 (64.2)                | <0.001  |

Values are presented as mean±standard deviation, number (%) or median (interquartile range).
DRE, digital rectal examination; PSA, prostate-specific antigen; PSAD, PSA density; PSAD-TZ, PSAD of transition zone volume; TRUS, transrectal ultrasound.

TABLE 3. Simple and multiple logistic regression model analyzing the predictors of high-grade prostate cancer (Gleason score ≥ 7) in 291 patients

| Variable                        | Simple logistic regression | Multiple logistic regression |
|---------------------------------|----------------------------|----------------------------|
|                                 | OR 95% CI                   | p-value                    |
|                                 | OR 95% CI                   | p-value                    |
| Age                             | 1.07 1.05–1.09              | <0.001                     |
| Nodule on DRE                   | 6.84 4.83–9.69              | <0.001                     |
| PSA                             | 1.03 1.02–1.04              | <0.001                     |
| Prostate volume                 | 0.99 0.98–1.00              | 0.005                      |
| Transitional zone volume        | 0.98 0.97–0.99              | 0.002                      |
| PSAD                            | 6.98 4.73–10.31             | <0.001                     |
| PSAD-TZ                         | 2.05 1.78–2.37              | <0.001                     |
| Hypoechoic lesion on TRUS       | 3.83 2.74–5.33              | <0.001                     |

OR, odds ratio; CI, confidence interval; DRE, digital rectal examination; PSA, prostate-specific antigen; PSAD, PSA density; PSAD-TZ, PSAD of transition zone volume; TRUS, transrectal ultrasound.

DISCUSSION

The incidence of PCa has been rapidly increasing and this phenomenon is currently a major health issue worldwide. Because early detection of PCa has been a primary concern in the last several decades, various studies of PCa screening have been performed [11-13]. However, although previous studies of PCa screening have demonstrated the improvements in PCa diagnosis, overdiagnosis of clinically insignificant PCa is considered to be the major problem causing increased costs and burden. Recent PCa studies have focused on the current issues in identifying clinically significant PCa [14-16].

In our study, patients with PCa who had hypoechoic lesions on TRUS had more aggressive pathological disease than did those who did not have hypoechoic lesions. Other studies have also reported methods for predicting aggressive forms of PCa. Newton et al. [17] concluded that prostate volume is inversely associated with high-grade PCa as well as extraprostatic extension and positive surgical margins. We also identified small prostate volume and small TZ volume of the prostate as significant risk factors for high-grade PCa in the simple logistic regression analysis; however, they were not significant by multiple logistic regression analysis. Another study suggested that the results of contrast-enhanced sonography with micro flow imaging are associated with the aggressiveness of PCa [18].

The significant majority of PCa originates from the peripheral zone. Hence, all hypoechoic lesions within the peripheral zone should be noted and included in the biopsy material. However, lack of a hypoechoic area does not preclude proceeding with biopsy, because 40% of cancers are isoechoic or hyperechoic on TRUS [19]. There has been controversy about the advantages and drawbacks of TRUS. TRUS biopsies are presently the method of choice for determining PCa [20-22]. However, Flanigan et al. [23] mentioned the limited accuracy of TRUS in identifying and localizing PCa. Chang et al. [24] reported that 55% to 60% of all small hypoechoic lesions in the posterior prostate ultimately prove to be benign and, therefore, refinement of the ultrasound criteria for identifying the lesions to which immediate attention should be paid is necessary. Ellis et al. [25] reported that performing biopsy of only hypoechoic sectors would have misdiagnosed 24.6% of the patients with PCa and that only 6.3% of patients with normal DRE results and a PSA level of less than 4.0 ng/mL demonstrated...
PCa on biopsy.

In the present study, more than half of the patients with hypoechoic lesions on TRUS did not have PCa and 2.7% of patients with normal DRE results and PSA levels of less than 4.0 ng/mL were diagnosed as having PCa on biopsy. Babaian et al. [26] suggested the relationship of PSA levels to other detection techniques and to the finding of cancer. In that analysis, PCa that was diagnosed by TRUS alone was least likely to be cancer (positive predictive values, 5.4%). Therefore, the present study demonstrates that TRUS may not be a screening method for PCa and that hypoechoic lesions on TRUS do not guarantee the presence of PCa. However, once PCa exists in the prostate, hypoechoic lesions on TRUS could imply its pathological aggressiveness.

Several studies have shown that abnormal DRE findings are related with more progressive forms of PCa. Okotie et al. [27] found that a substantial proportion of PCa detected by DRE at PSA levels less than 4 ng/mL has features associated with clinically aggressive tumors and concluded that DRE is useful in diagnosing biologically aggressive PCa and provides important prognostic information. According to Gosselaar et al. [28,29], men who had an abnormal DRE result would have a high chance of detection of aggressive PCa (Gleason score >7), indicating that an abnormal DRE finding is associated with clinically significant PCa. The findings of our study were consistent with these previous studies.

CONCLUSIONS

PCa was detected in about half of patients with hypoechoic lesions on TRUS. Patients with PCa who had hypoechoic lesions on TRUS had more aggressive pathological disease than did those who did not have hypoechoic lesions. Therefore, hypoechoic lesions on TRUS can be a marker for clinically significant PCa.

Although the widespread use of screening methods has led to increased diagnosis of PCa, the issue of overdiagnosis has been raised recently. Additional studies are required for determining the pathological features and the clinical significance of PCa. With the rapid advent of new technologies, combining new strategies and guidelines will be suggested to improve the quality of PCa evaluation.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

ACKNOWLEDGMENTS

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No.2011-0020128).

REFERENCES

1. Watanabe H, Igari D, Tanahasi Y, Harada K, Saito M. Development and application of new equipment for transrectal ultrasonography. J Clin Ultrasound 1974;2:91-8.
2. Smith JA Jr. Transrectal ultrasonography for the detection and staging of carcinoma of the prostate. J Clin Ultrasound 1996;24:455-61.
3. Langer JE. The current role of transrectal ultrasonography in the evaluation of prostate carcinoma. Semin Roentgenol 1999;34:284-94.
4. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-32.
5. Hall RR. Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument against. Eur Urol 1996;29 Suppl 2:24-6.
6. Applewhite JC, Matlagn BR, McCullough DL, Hall MC. Transrectal ultrasound and biopsy in the early diagnosis of prostate cancer. Cancer Control 2001;8:141-50.
7. Hou AH, Swanson D, Bangawi BA. Modalities for imaging of prostate cancer. Adv Urol 2009;518065.
8. Sano F, Teras H, Kawahara T, Miyoshi Y, Sasaki T, Noguchi K, et al. Contrast-enhanced ultrasonography of the prostate: various imaging findings that indicate prostate cancer. BJU Int 2011;107:1404-10.
9. Nishida S, Kinoshita H, Mishima T, Kurokawa H, Sakaoda N, Matsuda T. Prostate cancer detection by prebiopsy 3.0-Tesla magnetic resonance imaging. Int J Urol 2011;18:653-8.
10. Durkan GC, Greene DR. Diagnostic dilemmas in detection of prostate cancer in patients undergoing transrectal ultrasound-guided needle biopsy of the prostate. Prostate Cancer Prostatic Dis 2000;3:13-20.
11. Gosselaar C, Roobol MJ, Roemeling W, Wolters T, van Leenders GJ, Schroder FH. The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer. BJU Int 2008;101:685-90.
12. Abu Farsakh MG, Abu Farsakh HA. Serum prostate-specific antigen, radiologic findings and Gleason score in prostate biopsies in Jordan. Hematol Oncol Stem Cell Ther 2008;1:171-4.
13. Wolf JS Jr, Shinohara K, Carroll PR, Narayan P. Combined role of transrectal ultrasonography, Gleason score, and prostate-specific antigen in predicting organ-confined prostate cancer. Urology 1993;42:131-7.
14. Smith RP, Malkowicz SB, Whittington R, VanArsdalen K, Tochner Z, Wein AJ. Identification of clinically significant prostate cancer by prostate-specific antigen screening. Arch Intern Med 2004;164:1227-30.
15. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-90.
16. Ploussard G, Epstein JL, Montironi R, Carroll PR, Wirth M, Grimm MO, et al. The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 2011;60:291-303.
17. Newton MR, Phillips S, Chang SS, Clark PE, Cookson MS, Davis R, et al. Smaller prostate size predicts high grade prostate cancer at final pathology. J Urol 2010;184:930-7.
18. Xie SW, Li FH, Li HL, Du J, Xiao JG, Fang H, et al. Value of contrast-enhanced sonography with micro flow imaging in the diagnosis of prostate cancer. J Clin Ultrasound 2011;39:371-7.
19. Littrup PJ, Bailey SE. Prostate cancer: the role of transrectal ultrasound and its impact on cancer detection and management. Radiol Clin North Am 2000;38:87-113.
20. Hodge KK, McNeal JE, Stamey TA. Ultrasound guided trans-
rectal core biopsies of the palpably abnormal prostate. J Urol 1989;142:66-70.

21. Loch T, Eppelmann U, Lehmann J, Wullich B, Loch A, Stockle M. Transrectal ultrasonic guided biopsy of the prostate: random sextant versus biopsies of sono-morphologically suspicious lesions. World J Urol 2004;22:357-60.

22. Sperandeo G, Sperandeo M, Morcaldi M, Caturelli E, Dimitri L, Camagna A. Transrectal ultrasonography for the early diagnosis of adenocarcinoma of the prostate: a new maneuver designed to improve the differentiation of malignant and benign lesions. J Urol 2003;169:607-10.

23. Flanigan RC, Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, et al. Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. J Urol 1994;152(5 Pt 1):1506-9.

24. Chang JJ, Shinohara K, Bhargava V, Presti JC Jr. Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. J Urol 1998;160(6 Pt 1):2111-4.

25. Ellis WJ, Chetner MP, Preston SD, Brawer MK. Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 1994;152(5 Pt 1):1520-5.

26. Babaian RJ, Mettlin C, Kane R, Murphy GP, Lee F, Drago JR, et al. The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography. Findings of the American Cancer Society National Prostate Cancer Detection Project. Cancer 1992;69:1195-200.

27. Okotie OT, Roehl KA, Han M, Loeb S, Gashiti SN, Catalona WJ. Characteristics of prostate cancer detected by digital rectal examination only. Urology 2007;70:1117-20.

28. Gosselaar C, Roobol MJ, Roemeling S, van der Kwast TH, Schroder FH. Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics. Prostate 2007;67:154-61.

29. Gosselaar C, Roobol MJ, Roemeling S, Schroder FH. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Eur Urol 2008;54:581-8.